HIV Drug Resistance: New Insight and Updated Practices

I. Drug-Resistant HIV Transmission

Drug-resistance testing has come to be recognized as an important tool in tracking the growing and troublesome prevalence of transmitted drug-resistant HIV—a problem that appears to be here to stay. To provide PRN members with an update, Dr. Kuritzkes highlighted recent epidemiological data from around the world, looking at different patterns of resistance in both newly infected and chronically infected individuals.

Some of the most intriguing epidemiological data come from the CATCH study, which involved 17 European countries, evaluating the incidence of genotypic resistance in more than 1,600 infected HIV-positive individuals (Wensing, 2003). The overall prevalence of HIV strains resistant to at least one antiretroviral agent was 9.6%. “What was interesting about this study was that it was able to divide patients into two groups: those who had been infected for a year or less and those who had been infected for longer than a year, based on the physician’s assessment of infection time,” Dr. Kuritzkes said. According to the data presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, held in July 2003 in Paris, the prevalence of drug-resistant HIV among patients infected for a year or less was 10.9%, compared to a prevalence rate of 7.5% among patients infected for more than a year.

Also presented at the 2nd IAS conference were data from the United States, demonstrating similar results. In this study, the prevalence of drug-resistant HIV was assessed among 949 newly infected, antiretroviral-naïve individuals in 10 cities (Bennett, 2003). Using the stahrs testing algorithm, the investigators determined that 182 patients had been infected within four to six months (primary HIV infection), whereas the remaining 767 patients had been infected for at least six months (chronic HIV infection). Among the patients with primary HIV infection, approximately 11.5% had evidence of resistance to at least one antiretroviral agent. As for patients with chronic HIV infection, approximately 7.5% had evidence of resistance to at least one antiretroviral agent—results similar to the CATCH study. In both studies, resistance to nucleoside reverse transcriptase inhibitors was the most common, followed by resistance to the non-nucleoside reverse transcriptase inhibitors and then the protease inhibitors.

“Not only do the CATCH study and the U.S. study indicate a trend toward increasing prevalence of drug resistance in newly infected individuals,” Dr. Kuritzkes commented, “they also illustrated that drug-resistant HIV persists in plasma for an extended period of time, after transmission has occurred.”

In conflict with the CATCH and U.S.-based studies are data reported at the 11th Conference on Retroviruses and Opportunistic Infections (cROI) suggesting that the prevalence of drug-resistant HIV transmission is actually stabilizing or decreasing. In one study, reporting on new HIV infections at the Academic Medical Center of the University of Amsterdam and the Amsterdam Cohort Studies, the prevalence of transmitted HIV resistant to at least one antiretroviral agent decreased from 20% between the years of 1994 and 1997 to 6% between the years 1998 and 2002 (Bezemer, 2004). And in North Carolina, among the 12 individuals diagnosed with primary HIV infection between January 1998 and June 2000, approximately one-quarter of them had evidence of phenotypic resistance to at least one antiretroviral agent (Hicks, 2004). However, since June 2000, there have been no cases of phenotypic resistance in 18 individuals diagnosed with primary HIV infection.

“An explanation for the North Carolina data is not readily available,” Dr. Kuritzkes confessed. “However, it’s important to note that a lot of HIV transmission that has been occurring in recent years is among people of color with limited access to care. And the Adap waiting list is growing longer and longer, it’s possible that the limited care available in the state may be playing a hand in the reduction of transmitted drug-resistant HIV.” As such, differences in the prevalence of resistance, whether between regions or among specific populations, are likely to be important in determining patterns of transmission of resistant HIV.

The Persistence of Transmitted Drug-Resistant HIV

It was initially thought that transmitted drug-resistant HIV reverts rapidly to wild-type virus, given the usual absence of drug pressure, at least during the first years of infection. However, recent data—the CATCH and the U.S.-based studies notwithstanding—suggest that transmitted drug-resistant HIV can remain the dominant population in peripheral blood for an extended period of time (see Figure 1 on page 10). To explore this issue further, Dr. Kuritzkes reviewed a study analyzing baseline nucleotide sequences among 11 subjects with primary HIV infection who opted to defer antiretroviral therapy (Little, 2004). The patients had been infected for approximately 65 days and had at least one major drug-resistance mutation. Longitudinal samples were collected for a median of 225 days after infection and analyzed for persistence of
transmitted drug-resistant variants. Seven patients had evidence of NNRTI resistance, two patients had resistance to both NNRTIs and PIs, and one patient had triple-class resistance. The average time to reversion of the K103N variants to wild type in the seven patients with NNRTI resistance was 196 days following the estimated date of infection. In the four patients with mutations conferring resistance to protease inhibitors, no reversion to wild type was detected at 64, 191, 327, and 342 days after infection. Complete reversion of genotypic resistance was observed in only one patient at 1,019 days after infection.

“Obviously,” Dr. Kuritzkes pointed out, “the persistence of drug-resistant variants has significant implications for the treatment of treatment-naive subjects and subsequent secondary transmission of drug-resistant variants. The situation is very different than we had envisioned.”

As for the clinical consequences of transmitted drug-resistant HIV—the most notable being a compromising response to antiretroviral therapy—Dr. Kuritzkes reviewed some data presented at the 11th CROI by a team of investigators at Gilead Sciences (Borroto-Esoda, 2004). Study FTC-301A compared once-daily emtricitabine (Emtriva) to once-daily stavudine (Zerit), both combined with didanosine (Videx) and efavirenz (Sustiva), in 571 treatment-naive patients from North America, Latin America, and Europe. Overall, 90/546 (16%) evaluable patients entered the study with HIV mutations at positions associated with resistance to NNRTIs. There were no differences in the prevalence or type of mutations between the groups. For subjects with wild-type virus at baseline, the incidence of virologic failure was 12% in the stavudine group and 5% in the emtricitabine group. Among patients with drug-resistant virus at baseline, virologic failure occurred in 32% of the stavudine group and 13% of the emtricitabine group. “When we look at the numbers in this study,” Dr. Kuritzkes commented, “it looks as if approximately half of the treatment failures documented were among patients who entered the study with drug-resistant virus. The outcome of this study was determined by the inclusion of patients who had transmitted drug-resistant virus and highlights the importance of transmission of drug resistance in determining responses to an initial regimen in otherwise treatment-naive patients.”

II. The K65R Mutation

As was reviewed in the March 2004 issue of The PRN Notebook, in an article summarizing the mechanisms of HIV drug resistance based on a lecture by Dr. François Clavel, there are essentially two mechanisms by which resistance to NNRTI can occur. The first involves mutations that occur at or near the reverse transcriptase gene, resulting in increased drug discrimination by the enzyme. One mutation in particular, K65R, has come to be recognized as the “mutation of the year,” given its increasing incidence and prevalence and its propensity to cause at least some degree of resistance to tenofovir (Viread), stavudine, didanosine, zalcitabine (Hivid), abacavir (Ziagen), lamivudine (Epivir), and emtricitabine.

Perhaps the most widely cited case in point regarding the dangers of K65R is GlaxoSmithKline’s ES530009 trial (Gallant, 2003). In this study, 345 patients were randomized to receive either tenofovir or efavirenz, combined with a fixed-dose combination tablet containing 600 mg abacavir and 300 mg lamivudine, all to be taken once a day. Patients were naive to antiretroviral therapy prior to starting the study and had an average baseline viral load of 4.63 log10 copies/mL and a baseline CD4+ cell count of 260 cells/mm3. Because of a glaringly high number of treatment failures being documented in the triple-NNRTI group, the study investigators conducted an unplanned analysis involving the first 194 patients who completed eight weeks of follow-up. Approximately 49% of patients in the triple-NNRTI group met the definition of virologic failure, compared to only 5.4% patients in the efavirenz-based arm.

While the reason for the differences in response to therapy is still being debated, the most likely explanation involves a low genetic barrier that quickly allowed for the selection of resistance to this particular triple-NNRTI regimen. Tenofovir, abacavir, and lamivudine can all select for the K65R mutation. Among 21 patients who had viral loads that were high enough to test for drug resistance, 10 (48%) had the K65R mutation. “Tenofovir, abacavir, and lamivudine all exert concerted pressure on the reverse transcriptase gene. NNRTIs exert a blocking effect by plugging a nonextendable nucleoside analogue monophosphate to the 3’ end of the
Pyrophosphorolysis can be enhanced by key mutations, often referred to as thymidine analogue mutations (TAMs). While pyrophosphorolysis is believed to be the primary mechanism of resistance to zidovudine and stavudine, the process is not drug-specific in the way that discriminatory mutations tend to be. Consequently, these pyrophosphorolysis-enhancing mutations can confer reduced susceptibility to all of the nrtis.

In essence, nrti resistance is the sum of two mechanisms: 1) their ability to alter drug binding or incorporation, through the mechanism described in the beginning of this section, plus 2) their ability to alter the excision of drug from the nascent DNA chain. The 65R mutation impedes both drug binding and primer excision.

In effect, variants harboring both K65R and TAMs—still considered to be a rare occurrence—can have surprising effects. Many TAMs are in the “fingers” domain of the polymerase, which makes up the deoxynucleotide triphosphate binding site. In turn, TAMs interfere with proper function of the enzyme. Because K65R impedes primer excision, it is believed to sensitize HIV to nrtis affected by TAMs, most notably zidovudine. It has also been noted that TAMs can reverse some of the effects of K65R on drug binding and incorporation—there are data suggesting that concurrent zidovudine use can prevent the emergence of the K65R mutation—though the mechanism responsible for this has not yet been elucidated.

Of interest are data from six recent clinical trials evaluating all-reverse transcriptase inhibitor regimens containing tenofovir, either with or without zidovudine (see Table 1). Among patients initiating therapy for the first time, tenofovir-inclusive regimens not involving zidovudine were much more likely to fail in association with development of the K65R mutation. Conversely, tenofovir- and zidovudine-inclusive regimens were much more likely to fail in association with the development of TAMs.

### Table 1. K65R TAMs in Recent Clinical Trials

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Failures with K65R</th>
<th>Failures with TAMs</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Without zidovudine:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Didanosine + lamivudine + tenofovir</td>
<td>10/20 (50%)</td>
<td>NR</td>
<td>Jemsek, 2004</td>
</tr>
<tr>
<td>Abacavir + lamivudine + tenofovir</td>
<td>11/12 (92%)</td>
<td>NR</td>
<td>Landman, 2004</td>
</tr>
<tr>
<td>Abacavir + lamivudine + tenofovir</td>
<td>0%</td>
<td>10/21 (48%)</td>
<td>Gallant, 2003</td>
</tr>
<tr>
<td>Tenofovir + lamivudine + efavirenz</td>
<td>7/29 (24%)</td>
<td>0%</td>
<td>Gallant, 2003a</td>
</tr>
<tr>
<td><strong>Containing zidovudine:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trizivir (900) + tenofovir</td>
<td>1/8 (13%)</td>
<td>5/8 (63%)</td>
<td>Elion, 2004</td>
</tr>
<tr>
<td>Trizivir 8BID</td>
<td>0%</td>
<td>10/82 (12%)</td>
<td>Gulick, 2004</td>
</tr>
</tbody>
</table>

Source: Daniel Kuritzkes, MD

### III. The Role of Minor Variants

Moving on to resistance issues in heavily pre-treated HIV-positive patients, Dr. Kuritzkes reviewed data stemming from ACTG 398, a clinical trial designed to determine whether the addition of a second protease inhibitor to a regimen containing amprenavir (Agenerase) improved the 24-week response to salvage therapy (Mellors, 2003). The study enrolled 481 heavily pretreated HIV-positive patients: 21% had been on one protease inhibitor in the past, 53% had been on two prior protease inhibitors in the past, and 26% had been on three protease inhibitors in the past. Approximately 44% of the patients had also been on an nrti in the past.

All of the patients received efavirenz, adefovir dipivoxil, abacavir, and amprenavir. In addition, subjects were randomized to receive either placebo, nelfinavir (Viracept), saquinavir (Fortovase), or indinavir (Crixivan). There were no statistically significant differences between the three active drug arms. There was, however, a significant difference between the combined active arms and the placebo arm, demonstrating that dual protease inhibitor regimens are superior to single protease inhibitor regimens in heavily pretreated patients.

Not surprisingly, the ACTG 398 investigators reported that nrti-naive patients had significantly better responses than nrti-experienced patients: 84% of nrti-experienced patients, compared to 57% of the nrti-naive patients, failed to achieve an undetectable viral load after 24 weeks of follow-up. Of interest, though, is an analysis of the nrti-experienced patients. “When we break down the nrti-experienced patients into those who did or did not have evidence of nrti resistance at baseline, we see that patients who didn’t have evidence of nrti resistance seemed to do well during the first 24 weeks of the study,” Dr. Kuritzkes illustrated. After 24 weeks, however, the difference in response rates between these two groups became insignificant and eventually converged. “Why might this be?” Dr. Kuritzkes asked. “There must be something about the prior nrti exposure that predisposes this group of patients to fail the nrti regimen, compared to patients who have never been exposed to an nrti. And whatever that is, it is not being captured using standard resistance assays.”

### Single Genome Sequencing

Commercially available drug-resistance assays involve bulk sequencing, assessing the contribution of all RNA molecules in a plasma sample to generate what is, in essence, an average sequence where minor variants that are present are essentially silenced out by the strong signal from the majority population. An alternative method, Dr. Kuritzkes explained, is to perform single genome sequencing. In single genome sequencing, complementary DNA is derived from plasma RNA—using reverse transcriptase—and is then serially diluted to a single copy. From there, the single copy is amplified and sequenced.

The ACTG 398 study team employed this method to construct a phylogenetic analysis for one patient with nrti experience but no evidence of key nrti mutations, using standard drug-resistance testing at baseline. “This showed that there were 35 sequences from the same patient, the vast majority of which were wild type,” Dr. Kuritzkes explained in his review of the data. “However, two of the 35 sequences carried an nrti resistance mutation at codon 108. This is one of the mutations that contributes in a small but significant way to efavirenz resistance. And at the time of treatment failure, the virus that emerged carried the K103N mutation, in addition to the V108I mutation. In other words, the minority variant harboring the V108I mutation...”
In determining the success or failure of future therapy, it is important to understand these divergent TAM pathways (Hu, 2004). In a nutshell, these studies found that isolates carrying the T215Y mutation replicated more efficiently than isolates harboring the T215F mutation. With incorporation of the K70R mutation into isolates harboring the T215Y mutation, viral fitness was substantially reduced. Conversely, with the incorporation of the K70R mutation into isolates harboring the T215F mutation, there was a substantial growth advantage in the presence of zidovudine.

“In summary,” offered Dr. Kuritzkes, “we’ve learned that the T215Y pathway is more common and confers higher-level resistance to zidovudine and other TAMs, whereas viruses carrying T215F have lower replication capacity and are poorly fit.” With respect to the K70R mutation, Dr. Kuritzkes reiterated that it confers a significant advantage to HIV in the presence of zidovudine and that this mutation plays a much larger role in the development of zidovudine resistance than is usually considered.

IV. TAM Pathways

Reviewing some recent work in the area of thymidine analogue mutations, Dr. Kuritzkes explained that certain TAMs tend to occur together but that others are rarely found together in the same virus. For example, the M41L/L210W/T215Y pathway is a common TAM pattern and is associated with high-level resistance to zidovudine and with cross-resistance to other NRTIs, including tenofovir and abacavir. In contrast, the D67N/K70R/K219Q pathway is a less common TAM pattern and is associated with a lower fold resistance than the M41L/L210W/T215Y cluster. Dr. Kuritzkes also noted that the T215F mutation rarely appears in the reverse transcriptase of viruses also harboring the L210W mutation or the M41L mutation.

Dr. Kuritzkes’ group has conducted fitness and replication studies to better understand these divergent TAM pathways. In a nutshell, these studies found that isolates carrying the T215Y mutation replicated more efficiently than isolates harboring the T215F mutation. With incorporation of the L210W mutation into isolates harboring the T215Y mutation, viral fitness was substantially reduced. Conversely, with the incorporation of the K70R mutation into isolates harboring the T215F mutation, there was a substantial growth advantage in the presence of zidovudine.

V. M184V: The Plot Thickens

Perhaps the best known reverse transcriptase mutation is M184V, which is known to cause high-level resistance to lamivudine and emtricitabine. However, there have been studies suggesting that high-level resistance to lamivudine does not necessarily mean that the drug is rendered worthless. An example of this phenomenon can be found in a clinical trial of partial treatment interruptions conducted by Dr. Steven Deeks and his colleagues (Deeks, 2003). This study focused on a cohort of HIV-positive individuals who had a history of excellent treatment adherence, had drug-resistant viremia (greater than 400 copies/mL), and were experiencing a documented treatment-mediated benefit (e.g., a viral load below and CD4+ cell count above pretreatment levels). The patients either stopped their PI(s) or their NRTIs to determine the selective effects of these two drug classes in terms of maintaining the less-fit virus. “To everyone’s surprise,” Dr. Kuritzkes explained, “when the protease inhibitors were stopped in one group of patients, nothing happened. The virus continued to replicate at the same rate without any increase and only a small reemergence of wild-type in the protease gene. This benefit was attributed to the M184V mutation. By contrast, when the nucleoside analogues were stopped in the other group of patients, there was a half to three-quarter log increase in viral load.”

But do these data allow for the conclusion that lamivudine should be maintained in a failing regimen? To explore this further, a team of investigators that included Dr. Kuritzkes discontinued lamivudine in four highly treatment-experienced patients with no viable alternative treatment options and evidence of the M184V mutation while on a reg-
But, zidovudine appears to prevent the emergence of the K65R mutation. Dr. Kuritzkes explained. Reversion of M184V to wild type occurred in all four patients between six and 14 weeks, accompanied by an additional average increase in viral load of 0.3 log10 copies/mL. Upon resuming lamivudine therapy, the M184V mutation reappeared within eight weeks in all four patients.

However, in another study reviewed by Dr. Kuritzkes, the effects of lamivudine withdrawal in patients with the M184V mutation were less clear. The COLATE trial was an open-label trial involving 131 patients experiencing virologic failure while on a lamivudine-containing regimen (Dragsted, 2004). In switching to another regimen, approximately half of the patients were randomized to continue lamivudine therapy, with the remaining patients randomized to discontinue lamivudine treatment. Forty-eight weeks later, there were no significant differences between the two groups. “However,” Dr. Kuritzkes pointed out, “it’s important to note that this population of patients wasn’t as advanced as our group of patients. In turn, many of the patients responded well to therapy, which ended up swamping the relatively modest effect of residual lamivudine treatment.”

Conclusion

In summarizing his lecture, Dr. Kuritzkes reiterated that the transmission of drug-resistant HIV remains a serious problem to be reckoned with. “We’re seeing high rates of transmission and long-term persistence of drug-resistant HIV. This will have profound effects on responses to initial antiretroviral therapy. In turn, drug-resistance testing of newly diagnosed patients must become a routine practice.”

As for the K65R mutation, clinicians need to be aware of the daunting fact that it can result in multi-NNRTI resistance. However, K65R can render the virus hypersusceptible to zidovudine and may increase susceptibility of the virus to stavudine and abacavir, in the presence of TAMs. Plus, zidovudine appears to prevent the emergence of the K65R mutation.

Minor HIV variants, particularly those harboring drug-resistance mutations, remain a concern, particularly for HIV-positive patients who are highly treatment experienced. Dr. Kuritzkes reminded PRN members that drug-resistant variants are often undetected when present as 10% to 30% of a viral quasispecies population. “Because these drug-resistant variants can contribute to treatment failure, we need drug-resistance assays with improved sensitivity, to detect minor HIV variants and to adequately address the problems they pose.”

Finally, with respect to lamivudine, Dr. Kuritzkes stressed that clinicians should take some comfort in knowing that lamivudine retains partial activity against viral replication, despite the presence of the M184V mutation. “This is something that we’ve generally only seen in our highly treatment-experienced patients,” he said. “But our data does illustrate that lamivudine doesn’t become worthless simply because the M184V mutation is present.” Dr. Kuritzkes warns, however, that this observation does not, unfortunately, apply to other antiretrovirals. “With the NNRTIs,” he said, “there does not appear to be any lingering activity in the setting of NNRTI resistance.”

References


Gallant J, Pozniak A, Staszewski S, et al. Similar 96-week renal safety profile of tenofovir (XVR) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (ABC) in antiretroviral naive patients [Abstract S404]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2003a.


THE PRN NOTEBOOK® | VOLUME 9, NUMBER 3 | SEPTEMBER 2004 | WWW.PRN.ORG 13